Wilbanks Smith & Thomas Asset Management’s Denali Therapeutics DNLI Stock Holding History

Wilbanks Smith & Thomas Asset Management’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-5,381	Closed	-$240K	–	515
2021 Q4	$240K	Hold	5,381	–	–	0.01%	460
2021 Q3	$271K	Buy	+5,381	New	+$303K	0.01%	418
2018 Q4	–	Sell	-150	Closed	-$3K	–	585
2018 Q3	$3K	Buy	+150	New	+$2.48K	﹤0.01%	1321

Other funds holding DNLI

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

Wilbanks Smith & Thomas Asset Management's DNLI Position: Q1 2022 in Review

Wilbanks Smith & Thomas Asset Management sold out of Denali Therapeutics (DNLI) in Q1 2022, closing a stake of 5,381 shares — an estimated $240K sold.

Wilbanks Smith & Thomas Asset Management first reported a position in DNLI in Q3 2018 and held it in 3 quarters. The position peaked at $271K in Q3 2021. 190 funds tracked by Wall St. Rank hold DNLI as of Q1 2022.

Wilbanks Smith & Thomas Asset Management reported no remaining Denali Therapeutics position as of Q1 2022 after selling out during the quarter.
Wilbanks Smith & Thomas Asset Management sold 5,381 Denali Therapeutics shares in Q1 2022, an estimated $240K.
Wilbanks Smith & Thomas Asset Management first reported a position in Denali Therapeutics in Q3 2018 and held it in 3 quarters.
Wilbanks Smith & Thomas Asset Management's Denali Therapeutics position peaked at $271K in Q3 2021.
190 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2022.

Based on Wilbanks Smith & Thomas Asset Management's 13F filing for Q1 2022, filed 5 May 2022.